在天真与交换多发性硬化症患者中,二甲基酸盐与年龄相关的疗效:一个多中心基于人口的研究
Roberto De Masi1,2, Stefania Orlando1, Assunta Greco3
1Laboratory of Neuroproteomics, Multiple Sclerosis Centre, "F. Ferrari" Hospital, 73042 Casarano, Lecce, Italy.
Pharmaceuticals (Basel, Switzerland)
|November 27, 2025
概括
年龄显著影响多发性硬化症 (MS) 治疗结果. 服用二甲基烟酸 (DMF) 的老年患者经历了更大的残疾进展,无论先前的治疗史.
科学领域:
- 神经学 神经学
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
背景情况:
- 对多发性硬化症 (MS) 疾病修饰疗法 (DMT) 的年龄和时间依赖变量越来越感兴趣.
- 关于这些因素如何影响治疗反应和残疾的文献有限.
- 了解这些变量对于优化MS管理至关重要.
研究的目的:
- 研究时间依赖的变量对MS患者残疾累积和药物反应的影响.
- 评估二甲基酸盐 (DMF) 作为一线治疗的疗效.
- 加强DMF在不同患者群体中的风险益处评估.
主要方法:
- 现实世界的研究比较了 DMF 在天真与切换性MS 患者的疗效.
- 分析与患者年龄和治疗时间 (TinT) 相关的治疗结果.
- 包括169名患者 (74名天真者,95名切换者) 具有相似的TinT (5.9±2.3年).
主要成果:
- 与初学者患者相比,切换者患者的扩展残疾状态量表 (EDSS) 得分和年龄更高.
- 在两组中,年龄与疾病持续时间和EDSS正相关.
- 根据年龄调整的Kaplan-Meier分析显示,原始患者更频繁地保持较低的EDSS分数.
结论:
- 在接受DMF治疗的MS患者中,年龄是残疾进展的主要决定因素.
- 年龄独立地预测了DMF治疗的有效性,无论是天真的人群还是切换人群.
- 调查结果强调了年龄在评估DMF风险-收益概况时的重要性.
相关概念视频
Bioavailability Study Design: Healthy Subjects Versus Patients
136
Bioavailability studies are essential for evaluating a drug's therapeutic efficacy and understanding its absorption patterns under various physiological conditions. Conducting such studies on target patient populations provides more relevant data by simulating real-world disease states. However, practical challenges often necessitate the use of young, healthy adult volunteers as study subjects.Patients may exhibit altered drug absorption patterns due to the effects of the disease itself,...
136
Bioavailability Study Design: Single Versus Multiple Dose Studies
189
Bioavailability studies are essential for understanding how a drug is absorbed, distributed, metabolized, and excreted in the body. These studies assess the extent and rate at which the active pharmaceutical agent becomes available at the site of action. The design of bioavailability studies can involve single-dose or multiple-dose regimens, each with distinct advantages and limitations.Single-dose studies are the preferred approach due to their simplicity and reduced drug exposure for...
189
Bioequivalence studies: Biowaivers
210
Body:In certain scenarios, in vitro dissolution tests can replace in vivo bioequivalence studies. This is particularly true when a drug product, though available in varying strengths, maintains proportional similarity in its active and inactive ingredients. In such cases, the need for in vivo bioequivalence studies for lower strength variants may be waived, provided dissolution tests and in vivo studies on the highest strength yield satisfactory results.Bioequivalence can be indicated through...
210


